Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Therapeutics (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company, has announced its participation in the 8th Annual H.C. Wainwright MASH Investor Conference. The company, which focuses on developing treatments for various chronic organ diseases, will be represented by CEO Han Ying, PhD, who will present a company overview on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).
Investors and interested parties can access the live webcast of the presentation through the Events and Presentations page on Gyre's website. For those unable to attend the live session, a replay of the webcast will be made available following the event.
Gyre Therapeutics (Nasdaq: GYRE), una società di biotecnologia commerciale e autosostenibile, ha annunciato la sua partecipazione alla 8a Conferenza Annuale per Investitori H.C. Wainwright MASH. L'azienda, che si concentra sullo sviluppo di trattamenti per varie malattie croniche degli organi, sarà rappresentata dal CEO Han Ying, PhD, che presenterà una panoramica dell'azienda Lunedì 7 Ottobre 2024, alle 14:30 ET (11:30 AM PT).
Gli investitori e le parti interessate possono accedere alla diretta della presentazione tramite la pagina Eventi e Presentazioni del sito web di Gyre. Per coloro che non riescono a partecipare alla sessione live, sarà disponibile una replica della diretta dopo l'evento.
Gyre Therapeutics (Nasdaq: GYRE), una compañía de biotecnología en etapa comercial y autosostenible, ha anunciado su participación en la 8ª Conferencia Anual de Inversores H.C. Wainwright MASH. La empresa, que se centra en desarrollar tratamientos para diversas enfermedades crónicas de órganos, estará representada por CEO Han Ying, PhD, quien presentará una descripción general de la empresa el lunes 7 de octubre de 2024 a las 2:30 PM ET (11:30 AM PT).
Los inversores y partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de la página de Eventos y Presentaciones en el sitio web de Gyre. Para aquellos que no puedan asistir a la sesión en vivo, se hará disponible una repetición de la transmisión tras el evento.
Gyre Therapeutics (Nasdaq: GYRE)는 자급자족이 가능한 상업 단계의 생명공학 회사로서 제8회 H.C. Wainwright MASH 투자자 회의에 참가할 예정이라고 발표했습니다. 다양한 만성 장기 질환 치료제 개발에 집중하고 있는 이 회사는 CEO Han Ying, PhD가 2024년 10월 7일 월요일 오후 2시 30분 ET (오전 11시 30분 PT)에 회사 개요를 발표할 예정입니다.
투자자와 이해관계자는 Gyre 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 라이브 세션에 참석할 수 없는 분들을 위해 이벤트가 끝난 후 웹캐스트의 재생이 제공될 예정입니다.
Gyre Therapeutics (Nasdaq: GYRE), une entreprise de biotechnologie commercialement viable et autosuffisante, a annoncé sa participation à la 8ème Conférence Annuelle des Investisseurs H.C. Wainwright MASH. L'entreprise, qui se concentre sur le développement de traitements pour diverses maladies chroniques des organes, sera représentée par CEO Han Ying, PhD, qui présentera un aperçu de l'entreprise le lundi 7 octobre 2024 à 14h30 ET (11h30 PT).
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct de la présentation via la page Événements et Présentations du site Web de Gyre. Pour ceux qui ne peuvent pas assister à la session en direct, un enregistrement de la diffusion sera disponible après l'événement.
Gyre Therapeutics (Nasdaq: GYRE), ein selbsttragendes Biotechnologieunternehmen in der kommerziellen Phase, hat seine Teilnahme an der 8. jährlichen H.C. Wainwright MASH Investorenkonferenz bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für verschiedene chronische Organerkrankungen konzentriert, wird von CEO Han Ying, PhD vertreten, der am Montag, den 7. Oktober 2024, um 14:30 Uhr ET (11:30 Uhr PT) eine Unternehmensübersicht präsentieren wird.
Investoren und Interessierte können über die Seite für Veranstaltungen und Präsentationen auf der Gyre-Website auf die Live-Übertragung der Präsentation zugreifen. Für diejenigen, die an der Live-Sitzung nicht teilnehmen können, wird nach der Veranstaltung eine Wiederholung der Übertragung zur Verfügung gestellt.
- None.
- None.
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT).
The live webcast will be available on the Events and Presentations page of Gyre’s website. A webcast replay will be accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company’s experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
For Investors:
Stephen Jasper
stephen@gilmartinir.com
FAQ
When is Gyre Therapeutics (GYRE) presenting at the H.C. Wainwright MASH Investor Conference?
Who will be presenting for Gyre Therapeutics (GYRE) at the investor conference?
How can investors access Gyre Therapeutics' (GYRE) presentation at the H.C. Wainwright conference?
What is the focus of Gyre Therapeutics' (GYRE) clinical development programs?
